Show simple item record Anguiano Gómez, Lidia Riera Oliva, Marta Pascual Santos, Julio Soler, María José 2015-11-02T10:46:21Z 2015-11-02T10:46:21Z 2015
dc.identifier.citation Anguiano L, Riera M, Pascual J, Soler MJ. Endothelin Blockade in Diabetic Kidney Disease. J Clin Med. 2015 May 25;4(6):1171-92. doi: 10.3390/jcm4061171.
dc.identifier.issn 2077-0383
dc.description.abstract Diabetic kidney disease (DKD) remains the most common cause of chronic kidney disease and multiple therapeutic agents, primarily targeted at the renin-angiotensin system, have been assessed. Their only partial effectiveness in slowing down progression to end-stage renal disease, points out an evident need for additional effective therapies. In the context of diabetes, endothelin-1 (ET-1) has been implicated in vasoconstriction, renal injury, mesangial proliferation, glomerulosclerosis, fibrosis and inflammation, largely through activation of its endothelin A (ETA) receptor. Therefore, endothelin receptor antagonists have been proposed as potential drug targets. In experimental models of DKD, endothelin receptor antagonists have been described to improve renal injury and fibrosis, whereas clinical trials in DKD patients have shown an antiproteinuric effect. Currently, its renoprotective effect in a long-time clinical trial is being tested. This review focuses on the localization of endothelin receptors (ETA and ETB) within the kidney, as well as the ET-1 functions through them. In addition, we summarize the therapeutic benefit of endothelin receptor antagonists in experimental and human studies and the adverse effects that have been described.
dc.description.sponsorship This work was partially supported by a research grant ISCIII-FEDER PI14/00557.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher MDPI
dc.relation.ispartof Journal of Clinical Medicine. 2015 May 25;4(6):1171-92
dc.rights © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license/n(, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.subject.other Ronyons -- Malalties
dc.subject.other Diabetis
dc.title Endothelin Blockade in Diabetic Kidney Disease.
dc.type info:eu-repo/semantics/article
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


Compliant to Partaking